Trial · NCT02317627
Results by group214
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 214
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | 400 mg QD | ≥ 75% Reduction from Baseline | 16.7 | 95% Confidence Interval 2.1 to 48.4 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | 200 mg BID | ≥ 75% Reduction from Baseline | 8.3 | 95% Confidence Interval 0.2 to 38.5 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | 400 mg BID | ≥ 75% Reduction from Baseline | 9.1 | 95% Confidence Interval 0.2 to 41.3 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | Overall (All Subjects) | ≥ 75% Reduction from Baseline | 11.4 | 95% Confidence Interval 3.2 to 26.7 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | 400 mg QD | ≥ 50% Reduction from Baseline | 41.7 | 95% Confidence Interval 15.2 to 72.3 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | 200 mg BID | ≥ 50% Reduction from Baseline | 50.0 | 95% Confidence Interval 21.1 to 78.9 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | 400 mg BID | ≥ 50% Reduction from Baseline | 18.2 | 95% Confidence Interval 2.3 to 51.8 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population | Overall (All Subjects) | ≥ 50% Reduction from Baseline | 37.1 | 95% Confidence Interval 21.5 to 55.1 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | 400 mg QD | ≥ 75% Reduction from Baseline | 16.7 | 95% Confidence Interval 2.1 to 48.4 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | 200 mg BID | ≥ 75% Reduction from Baseline | 14.3 | 95% Confidence Interval 0.4 to 57.9 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | 400 mg BID | ≥ 75% Reduction from Baseline | 14.3 | 95% Confidence Interval 0.4 to 57.9 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | Overall (All Subjects) | ≥ 75% Reduction from Baseline | 15.4 | 95% Confidence Interval 4.4 to 34.9 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | 400 mg QD | ≥ 50% Reduction from Baseline | 41.7 | 95% Confidence Interval 15.2 to 72.3 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | 200 mg BID | ≥ 50% Reduction from Baseline | 71.4 | 95% Confidence Interval 29.0 to 96.3 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | 400 mg BID | ≥ 50% Reduction from Baseline | 28.6 | 95% Confidence Interval 3.7 to 71.0 | Percentage of participants (%) |
| Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population | Overall (All Subjects) | ≥ 50% Reduction from Baseline | 46.2 | 95% Confidence Interval 26.6 to 66.6 | Percentage of participants (%) |
| Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population | 400 mg QD | All AEs | 12 | Percentage of participants (%) | |
| Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population | 200 mg BID | All AEs | 11 | Percentage of participants (%) | |
| Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population | 400 mg BID | All AEs | 8 | Percentage of participants (%) | |
| Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population | Overall (All Subjects) | All AEs | 31 | Percentage of participants (%) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02317627/results